Hepatoprotective and Anti-Hepatitis effect of non pharmacopoeial compound formulation on CCl₄-induced hepatotoxicity in albino rats

47-51To evaluate the anti-hepatitis activity of non-pharmacopoeial compound formulation on CCl4 induces hepatotoxicity in albino rats.CCl4 is used to produce hepatic damage in albino rats in the dose of 2 mL/kg BW, i.p. for 6 days. The anti-hepatitis effect of low dose (70 mg/100 g), high dose (140 mg/100 g) and 50% ethanolic extract (15 mg/100 g) of non-pharmacopoeial compound formulation (Majoon) was assessed in CCl4 (2 mL/kg BW i.p.) induce hepatic damage in albino rats. The biochemical parameters such as SGOT (AST), SGPT (ALT), ALP, total bilirubin and total protein were estimated and the antioxidant activity was also estimated. These biochemical observations were supplemented by histopathological study of liver sections. Silymarin (10 mg/100 g B.W.p.o.) was used as a standard hepatoprotective drug for positive control. Data was analysed by one way ANOVA test. Administration of non-pharmacopoeial compound formulation and its extract significantly prevented CCl4 induced elevation of serum ALT, AST, ALP, total billirubin and total protein level. The histopathological study revealed hepatocytes regeneration. The test drug also decreases lipid peroxidaion. So, the test drug was found effective as anti-hepatitis and antioxidant effect. The result was comparable to that of Silymarin. The results of present study show that the compound formulation has significant anti-hepatitis activity